Research Notes
Long-form notes on peptides, supplements, and protocol design. Every PubMed citation live-verified by the INT-01 guardrail before publish; same engine that gates the calculators.
§ NOTE
Apr 30, 2026
BPC-157: Why FDA Category 1 Doesn't Mean Validated
BPC-157's reclassification to FDA Category 1 in February 2026 was a political decision, not a scientific one. Here's what 30 years of animal data, three tiny human pilots, and one upcoming RCT actually tell us, and what they don't.
Read more
§ NOTE
Apr 30, 2026
Cerebrolysin: The 50-Country Drug Without an FDA Story
Approved in Austria, Germany, Russia, China, Mexico, and ~50 other countries since 1976. Never filed at the FDA. The independent Cochrane review says no benefit on stroke mortality and signals harm; manufacturer-funded meta-analyses say modest motor-recovery benefit. Bryan Johnson tried it for three months and reported null biomarker effect. The US IV-clinic markup is 10-20× the Russian-pharmacy retail import price.
Read more
§ NOTE
Apr 30, 2026
KPV: The Anti-Inflammatory Tripeptide Awaiting Its July 2026 Hearing
KPV has 30+ years of mechanism, multiple animal-model studies for IBD and skin inflammation, and one human Phase IIa trial, but the trial tested a different molecule. The Pharmacy Compounding Advisory Committee reconsiders KPV's regulatory status July 23-24, 2026.
Read more
§ NOTE
Apr 30, 2026
MOTS-c: The Mitochondrial Peptide Behind the Longevity Hype
MOTS-c is a 16-amino-acid peptide your mitochondria already make, and it has 90+ animal studies behind it. It also has zero completed human dosing trials, an obesity paradox that contradicts the deficiency narrative, and a first-ever Phase 2a that won't read out until 2028.
Read more
§ NOTE
Apr 30, 2026
TB-500: What 30 Years of Thymosin Beta-4 Research Actually Shows
TB-500 has the strongest clinical trial base of any research peptide on the gray market, and it still does not validate the way most people use it. Here is what the published Tβ4 evidence supports, and what the SubQ injury-recovery protocols are inventing.
Read more